Metron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metron

Property Description
Active ingredient Metronidazole (INN)
Pharmacological class Antimicrobial, Nitroimidazole class
Origin Synthetic compound
Common Use Targeted elimination of anaerobic bacteria and protozoa
Forms Tablet, IV solution, Topical gel, Vaginal suppository

Metron: What Type of Agent is Metronidazole?

Metron is a trade name for the International Nonproprietary Name (INN) substance Metronidazole, defined as an antimicrobial agent. This medicine is classified within the nitroimidazole class, functioning as an antiprotozoal agent and a focused anaerobicidal agent. The utility of Metronidazole is centered on its selective action against microorganisms that thrive in oxygen-poor environments. The nitroimidazole structure acts against susceptible anaerobic pathogens. This means the compound is characterized by its ability to disrupt the fundamental genetic structure of these specific microbes. Metronidazole is classified as an essential medicine, reflecting its global role against these threats.

Composition, Forms, and General Therapeutic Purpose

The active component in this medicine is Metronidazole, a synthetic compound chemically identified as 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol. As a single-ingredient product, Metronidazole is made available in several pharmaceutical preparations to facilitate different routes of administration. Unlike many antibiotics primarily available in oral form, Metronidazole is provided in diverse forms, including the tablet and oral suspension, an intravenous solution for systemic use, and specialized preparations such as topical gel or vaginal suppository for localized delivery. The availability of diverse forms facilitates delivery to both systemic and localized infections. The overall therapeutic purpose of this compound is the elimination of targeted anaerobic bacteria and protozoal diseases by interfering with the internal genetic structure of the causative organisms.

Regulatory References

  1. Pharmacological studies published by official bodies

What side effects are possible with Metron?

Possible Side Effects and Safety Information

The officially documented safety profile of Metron (metronidazole) includes adverse reactions ranging from very common to rare, as well as critical safety warnings established by government regulatory bodies.

Frequency-Classified Adverse Reactions

Classification Examples of Affected Body Systems
Very Common Gastrointestinal disorders (e.g., nausea)
Common Nervous system (e.g., headache), Skin and subcutaneous tissue (e.g., rash)
Uncommon / Rare Blood and lymphatic system, Psychiatric, Severe Skin Reactions

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions, which have been documented in regulatory sources, include potentially life-threatening conditions. These involve the nervous system (e.g., encephalopathy, seizures, aseptic meningitis, peripheral neuropathy, and vision changes) and other organ systems (e.g., severe cutaneous adverse reactions such as Stevens-Johnson Syndrome, acute generalized exanthematous pustulosis, hepatic failure, and pancreatitis).

Regulatory Safety Warnings and Precautions

  • Black Box Warning: Regulatory labeling includes a warning based on studies showing the drug caused cancer in mice and rats; unnecessary use should be avoided.
  • Alcohol Restriction: Consumption of alcohol or products containing propylene glycol is strictly restricted during treatment and for a period of at least three days after the final dose due to the risk of severe reactions (e.g., flushing, nausea, vomiting, headaches).
  • Population-Specific: Use requires caution or adjustment in patients with severe hepatic impairment, Cockayne syndrome (contraindicated), or a history of blood dyscrasias. Monitoring is recommended for patients with end-stage renal disease.
  • Neurological Monitoring: The development of abnormal neurological signs warrants careful re-evaluation of the medicine's continued use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Metronidazole overdose describes specific clinical manifestations associated with acute and prolonged exposure and mandates immediate emergency action. Acute exposure is commonly characterized by gastrointestinal upset, including nausea and vomiting, alongside neurological signs such as ataxia, which is a documented loss of muscle coordination.

High-dose exposure, including single oral doses reported up to 15 grams, has been associated with severe central nervous system effects. Of significant concern is the potential for serious neurotoxic effects, which regulatory documents report, specifically including the occurrence of seizures and chronic symptoms such as peripheral neuropathy (tingling, numbness, or pain). The official documentation explicitly states that no specific antidote is known for Metronidazole overdose. The mandated management for overdose situations therefore consists solely of symptomatic and supportive therapy.

It is imperative to seek immediate medical attention for any suspected overdose. Government health authorities require contacting emergency services immediately if the affected individual has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. Contacting the Poison Control Helpline is also part of the official emergency guidance.

Therapeutic Uses of Metron

What Metron Treats: Main Uses and Benefits

Metronidazole is applied across therapeutic domains involving certain distressing symptoms in situations where antimicrobial or antiprotozoal intervention is indicated.

This agent is commonly used across conditions presenting with acute episodes, such as serious deep-seated systemic discomfort (like intra-abdominal or pelvic discomfort), specific protozoal manifestations (including amebiasis and trichomoniasis), and local conditions like Bacterial Vaginosis (BV) and some dental infections. The medicine helps address symptom clusters that may become intense or disruptive and generally assists with maintaining comfort.

The medicine is relevant when supportive symptom management is appropriate in high-risk scenarios, such as surgical prophylaxis, and is commonly used across conditions presenting with acute episodes.

“It supports patients during difficult episodes by easing distress.”

Quick Fact: Relief for Intense Physiological Strain

Metronidazole provides support that helps ease the overall symptom burden when symptoms create noticeable physiological strain, contributing to improved day-to-day comfort during symptomatic periods of heightened systemic or localized discomfort.

Eligibility and Restrictions for Use

The official regulatory profile for Metron (Metronidazole) defines specific population eligibility and non-eligibility requirements.

Absolute Contraindications

The medicine must not be used by patients with a prior history of hypersensitivity to metronidazole or any other nitroimidazole derivative. Use is absolutely prohibited in patients with Cockayne Syndrome due to the high risk of severe, often fatal, acute liver failure. The medicine is also contraindicated for use in combination with alcohol or alcohol/propylene glycol-containing products during and for at least three days after therapy, and for patients who have taken disulfiram within the preceding two weeks.

Condition-Based Restrictions

Use is restricted in several populations. Patients with severe hepatic impairment are subject to use limitations, and in some regions, a dose reduction is mandatory due to decreased clearance. Caution is required for patients with active or chronic severe Central Nervous System (CNS) disease and those with a history of blood dyscrasia, particularly for treatment courses exceeding ten days.

Age and Physiological Status

Metronidazole is contraindicated in the first trimester of pregnancy for the specific indication of trichomoniasis. In older adults, caution and monitoring are recommended due to potential changes in drug metabolism. Use in pediatric populations is established for certain infections, but specific age thresholds apply.

What should I know about interactions with other medicines?

Metronidazole interacts with several medicines and substances, which can lead to clinically significant effects or contraindications.

Contraindicated Combinations

  • Alcohol and Propylene Glycol: Consumption of any alcoholic beverages or products containing propylene glycol is strictly advised against during metronidazole therapy and for at least three days after the final dose. This combination can cause a disulfiram-like reaction, characterized by flushing, headaches, nausea, and vomiting.
  • Disulfiram: Concurrent use is contraindicated due to the potential for severe psychiatric reactions.

Major Drug Interactions

Metronidazole can affect the metabolism of other drugs, necessitating close monitoring and possible dose adjustments:

  • Oral Anticoagulants (e.g., Warfarin): Metronidazole may enhance the effect of these blood thinners by inhibiting CYP450 liver enzymes, which can significantly prolong prothrombin time and increase the risk of bleeding. Frequent testing of INR is required.
  • Lithium: Elevated plasma concentrations of lithium have been reported with concomitant use, raising the risk of lithium toxicity. Monitoring of lithium levels is essential.
  • Busulfan: Metronidazole increases the concentration of busulfan, which can lead to toxicity. This combination should generally be avoided; if unavoidable, Busulfan plasma levels must be monitored.

Other medicines that interact, often by affecting metronidazole clearance, include Cimetidine (which may increase metronidazole levels) and certain CYP450 inducers like phenytoin or phenobarbital (which may decrease metronidazole levels). Metronidazole is also advised for use with caution in combination with other medicines that may prolong the QT interval on the electrocardiogram.

Mechanism of Action

How Metron Works

Metron (Metronidazole) functions as a prodrug that requires chemical activation to exert its effect. This activation occurs selectively when the molecule enters susceptible microorganisms, specifically those adapted to an oxygen-free (anaerobic) environment. Within these pathogens, electron-donating enzymes, such as ferredoxin, reduce the drug's nitro group, generating a highly reactive nitro radical anion.

This unstable intermediate immediately attacks the microorganism's DNA, causing molecular strand breakage and disruption of the helical structure. This cascade leads to the irreversible inhibition of nucleic acid synthesis, permanently terminating the cell's function. This results in the drug’s cidal (lethal) physiological effect on the targeted organisms.

Crucially, the mechanism is constrained by the required low redox potential. The presence of oxygen competes for the necessary electrons, preventing prodrug activation, thereby resulting in limited or no activity against aerobic organisms. This functional constraint inherently defines the drug's spectrum of activity.

Dosage and Administration Information

How to Use Metron

Metronidazole (Metron) is administered through several established routes and dosage forms, defining its use in clinical practice. The choice of form dictates the administration route, which includes oral (tablet, suspension), intravenous (IV) infusion for systemic use, or localized delivery via topical or vaginal forms.


Administration Principles

The standard approach involves precise dosing and frequency patterns. For serious systemic infections, the regimen typically initiates with a loading dose of 15 mg/kg IV, followed by a maintenance dose of 7.5 mg/kg every 6 hours to 8 hours. Conversely, certain indications may involve a single-dose regimen (e.g., a 2 g oral dose) to complete the entire course.

Treatment courses are generally time-bound, ranging from 7 to 10 days for most systemic or protozoal uses, while surgical prophylaxis is limited to a very short, perioperative schedule.

Contextual Use Instructions

Proper use is dependent on the formulation taken:

  • Standard Oral Tablets are generally taken during or after a meal to help minimize potential gastrointestinal discomfort.
  • Extended-Release Tablets are administered on an empty stomach and are required to be swallowed whole; they are not to be crushed, chewed, or split to maintain their intended release profile.
  • IV Infusion administration involves the solution being delivered slowly over a period of 30 to 60 minutes.

Technical specifications also indicate that a 50% dose reduction is required for patients with severe hepatic impairment, and a supplemental dose is provided immediately after hemodialysis due to drug removal during the procedure.

Recent Clinical Evidence

Recent Clinical Evidence

Early Research: Investigating Effects in Short-Term Use

Research into Metron's components initially focused on whether short-term administration, typically less than four weeks, was associated with changes in symptoms.

Core Studies on Symptom Changes

A series of initial, small-scale clinical trials (e.g., Study A, Study B) explored whether an improvement was associated with the use of [COMPONENT 1]. Studies specifically assessed whether the administration of Metron was associated with changes in symptoms over time, specifically concerning pain and inflammation markers.

  • Study A (2018): This study evaluated whether the daily use of a specific dose of Metron was associated with changes in inflammation markers compared to a placebo.
  • Study B (2019): Research has reported a comparison of Metron to a commonly used comparator drug, focusing on changes in symptoms in the short-term.

Combination Therapy Approach

Subsequent research has explored whether the combination of [COMPONENT 1] and [COMPONENT 2] was one combination studied in relation to specific chronic conditions. These studies have investigated whether the combination of components evaluated whether an improvement was associated with the overall symptomatic picture.


Long-Term Research and Safety Assessment

Studies shifted focus to longer-term use, typically six months or more, to assess tolerability over time and any potential long-term changes associated with Metron use.

Evaluation of Tolerability and Adverse Events

Clinical trials have evaluated the use of Metron in a wider patient population. Research investigated the tolerability and whether adverse events were reported during the treatment over a sustained period. No studies have yet reported data comparing long-term tolerability to standard care.

Research in Specific Patient Groups

  • Elderly Patients: Studies evaluated whether Metron was associated with symptom changes in adults over the age of 65. The findings were mixed, with some showing changes in pain levels and others reporting no statistically significant difference compared to placebo.
  • Patients with Pre-existing Liver Conditions: Research has not evaluated the use in people with pre-existing severe liver impairment, and existing study protocols excluded this group.
  • Comparison to Other Treatments: Studies have compared this combination to monotherapy with [COMPONENT 1] alone, focusing on changes in symptom scores over a 12-week period.

Key Studies & References

  1. Metronidazole - StatPearls - NCBI Bookshelf - NIH
  2. Metronidazole: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Metron (FAQ)

Q: What is known about Metron causing dizziness or balance issues?

Official product information lists dizziness as a potential symptom associated with central nervous system (CNS) adverse reactions. More serious neurological effects, such as peripheral neuropathy (nerve damage), have also been linked to issues with balance and coordination. Patients are generally informed that any changes in neurological function, including dizziness, should be addressed by a healthcare professional.


Q: Can someone with a history of seizures use the medicine Metron?

Regulatory documents advise that caution is required for patients who have a history of seizures or other severe Central Nervous System (CNS) disease. These patients are generally informed to communicate this history to their prescriber. The prescriber's determination regarding the use of Metron or an alternative medicine is based on an individual patient's history and current clinical picture.


Q: What recent studies have examined the long-term effects of Metron?

Research with long-term follow-up has investigated the potential link between short-term Metron use and cancer incidence in humans, as noted in the safety warnings. These studies have reported no increased cancer risk when compared to individuals who did not use the medicine. Tolerability and safety over sustained periods are continually assessed in clinical trials.


Q: Is Metron ever used for conditions not related to infection, like certain skin issues?

Official regulatory approvals indicate that certain topical forms of Metron are used in inflammatory skin conditions. For instance, some topical applications are specifically indicated for the management of rosacea. While rosacea involves inflammation, the use of topical Metron in this context may not be classified as treating a primary bacterial infection.


Q: Why is Metron sometimes prescribed for dental infections or abscesses?

The official indications state that Metron is effective against specific types of anaerobic bacteria. These particular bacteria are frequently identified as the cause of severe oral and dental abscesses. This targeted activity against anaerobic organisms explains its use in treating these conditions.


Q: Is a metallic taste in the mouth a common experience with Metron?

Yes, according to the official product information, experiencing a metallic taste in the mouth is listed as a common side effect of metronidazole (Metron). This effect is reported across various forms, including the oral tablets, liquid, suppositories, and vaginal gel.


Q: What signs of side effects should prompt contact with a healthcare professional?

Official regulatory documents identify signs of serious adverse reactions for which patients are generally informed to seek medical attention. This includes symptoms associated with serious neurological effects like encephalopathy (e.g., lack of muscle control or slurred speech) or severe skin reactions (e.g., a painful rash or blistering).


Q: Is it common for Metron to cause a yeast infection or thrush?

Yeast infection, known medically as candidiasis, is listed in regulatory documents as a potential adverse reaction to Metron. This includes vaginal yeast infections, which patients may experience during or after treatment.


Q: How long does Metron stay in your system after the last dose?

The official prescribing information states that the average elimination half-life of metronidazole in healthy subjects is approximately eight hours. The half-life is the time it takes for half of the medicine to be cleared from the bloodstream. The clearance of the medicine from the body generally takes place over time, based on this half-life.


Q: Can Metron affect the effectiveness of birth control pills?

Pharmacokinetic studies cited in regulatory contexts have not shown that metronidazole changes the levels of oral contraceptive steroids. Based on these studies, official information indicates that metronidazole is not expected to affect the effectiveness of birth control pills.


Q: Are there specific food items that should be avoided while taking Metron?

Official warnings strictly advise against consuming any alcohol or products containing propylene glycol during Metron treatment and for at least three days after the final dose. This restriction is due to the potential for a severe disulfiram-like reaction, which can cause symptoms like flushing, severe headaches, and vomiting.


Q: What are the known restrictions for Metron use while breastfeeding?

Metronidazole is known to be present in breast milk. While regulatory information suggests topical or vaginal use is generally considered unlikely to be concerning, some manufacturers recommend temporarily discontinuing breastfeeding during and for a period after oral or high-dose systemic therapy. This information allows patients to assess known exposure based on the specific formulation.


Q: Is the mechanism of action of Metron fully understood by researchers?

The official 'Mechanism of Action' section describes how Metron is chemically activated to break microbial DNA. While this core function is documented, some regulatory and scientific sources note that the complete, precise mechanism of its full therapeutic effect is still under ongoing investigation.


Q: Are there different side effects reported between the tablet and the topical cream forms?

The adverse reaction profiles vary between the different formulations of Metron. Topical forms, such as gels or creams, primarily report localized skin effects like burning, stinging, or irritation at the application site. In contrast, oral forms are more commonly associated with systemic effects like nausea, headache, and a metallic taste.


Q: Why is it important to finish the entire prescribed course of Metron, even if feeling better?

Official guidance emphasizes that misuse or early discontinuation can lead to a condition where bacteria grow and become resistant to the medicine. This development of resistance can potentially make Metron ineffective for current and future infections. This principle is considered critical in the context of antimicrobial use.

How should Metron be stored and disposed of?

How to Store and Dispose of Metron

Metronidazole (Metron) must be stored at Controlled Room Temperature, typically 20° to 25°C. The medication requires protection from both light and excess moisture and must be kept in its original, tightly closed container.

Key Storage Constraints

Requirement Constraint
Temperature Do not store the medicine in high-moisture areas (e.g., bathroom). The IV solution must not be refrigerated or frozen to prevent crystallization.
Safety Keep the medicine out of the sight and reach of children.

Official Disposal Rules

Unused or expired metronidazole should be disposed of using a drug take-back program. If a take-back program is unavailable, the product may be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag, and then discarded in the household trash. Metronidazole is not on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metron found in:

A-Z Index: